Data / Drug companies / Medroxyprogesterone acetate
Medroxyprogesterone acetate: 23 companies and 48 products in the FDA NDC directory
Medroxyprogesterone acetate is listed in the FDA National Drug Code Directory by 23 companies, with 48 products in commercial distribution. 35 of the products (72.9%) are marketed under an abbreviated new drug application (ANDA), the generic route. The most common dosage forms are tablet; injection, suspension; injection, suspension, extended release, and the newest product started marketing on October 17, 2026.
SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.
- Companies listing it
- 23
- Products
- 48
- Generic (ANDA) products
- 35 (72.9%)
- Application numbers
- 13
- Routes
- Oral, Intramuscular, Subcutaneous
- Brand names
- Provera, Depo-Provera, Depo-SubQ Provera
- openFDA record search
- api.fda.gov
Companies that list medroxyprogesterone acetate
Ranked by number of products. Finished drugs in commercial distribution.
| Company | Products | Main dosage forms | Main marketing category | Newest product started |
|---|---|---|---|---|
| Pharmacia & Upjohn Company LLC | 6 | tablet; injection, suspension | New drug applications (NDA) | July 20, 2020 |
| A-S Medication Solutions | 5 | tablet; injection, suspension | Generic drugs (ANDA) | October 21, 2021 |
| Bryant Ranch Prepack | 4 | tablet | Generic drugs (ANDA) | December 4, 1996 |
| Remedyrepack Inc. | 4 | tablet; injection, suspension | Generic drugs (ANDA) | October 17, 2026 |
| Mylan Pharmaceuticals Inc. | 3 | tablet | Authorized generics (NDA) | August 20, 2018 |
| Teva Pharmaceuticals USA, Inc. | 3 | tablet | Generic drugs (ANDA) | December 4, 1996 |
| Amneal Pharmaceuticals LLC | 2 | injection, suspension | Generic drugs (ANDA) | June 13, 2023 |
| Amphastar Pharmaceuticals, Inc. | 2 | injection, suspension, extended release | Generic drugs (ANDA) | November 28, 2017 |
| Eugia US LLC | 2 | injection, suspension | Generic drugs (ANDA) | August 31, 2022 |
| Prasco Laboratories | 2 | injection, suspension | Authorized generics (NDA) | October 21, 2021 |
| Preferred Pharmaceuticals Inc. | 2 | tablet | Generic drugs (ANDA) | December 6, 2021 |
| Sun Pharmaceutical Industries, Inc. | 2 | injection, suspension | Generic drugs (ANDA) | May 4, 2019 |
| American Health Packaging | 1 | tablet | Generic drugs (ANDA) | April 5, 2016 |
| Amneal Pharmaceuticals NY LLC | 1 | injection, suspension | Generic drugs (ANDA) | June 10, 2025 |
| Coupler LLC | 1 | tablet | Generic drugs (ANDA) | January 30, 2025 |
| Hikma Pharmaceuticals USA Inc. | 1 | injection, suspension | Generic drugs (ANDA) | May 1, 2023 |
| Mylan Institutional LLC | 1 | injection, suspension | Generic drugs (ANDA) | October 12, 2018 |
| Northwind Health Company, LLC | 1 | tablet | Generic drugs (ANDA) | December 27, 2023 |
| NuCare Pharmaceuticals,Inc. | 1 | tablet | Generic drugs (ANDA) | December 4, 1996 |
| PD-Rx Pharmaceuticals, Inc. | 1 | tablet | Generic drugs (ANDA) | December 4, 1996 |
| PD-Rx Pharmaceuticals, Inc. | 1 | tablet | Generic drugs (ANDA) | December 4, 1996 |
| Proficient Rx LP | 1 | tablet | Generic drugs (ANDA) | December 4, 1996 |
| Xiromed, LLC | 1 | injection, suspension | Generic drugs (ANDA) | March 12, 2024 |
Dosage forms
| Dosage form | Products | Share |
|---|---|---|
| Tablet | 28 | 58.3% |
| Injection, suspension | 18 | 37.5% |
| Injection, suspension, extended release | 2 | 4.2% |
Marketing categories
| Marketing category | Products | Share |
|---|---|---|
| Generic drugs (ANDA) | 35 | 72.9% |
| Authorized generics (NDA) | 7 | 14.6% |
| New drug applications (NDA) | 6 | 12.5% |
Pharmacologic classes
| Class | Products |
|---|---|
| Progestin | 48 |
Updated November 6, 2026. Read from US Food and Drug Administration, National Drug Code Directory (openFDA). CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.